Business Wire

New Phase 3 STELARA® (ustekinumab) Data Show Positive Results as Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

Jaa

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3 UNIFI maintenance study. The data showed that a significantly greater proportion of adults with moderate to severe ulcerative colitis (UC) receiving ustekinumab subcutaneous (SC) maintenance therapy were in clinical remission* at Week 44, compared to patients receiving placebo – the study’s primary endpoint.1 Patients receiving ustekinumab SC maintenance therapy had a clinical response 8 weeks after receiving a single intravenous (IV) dose of ustekinumab.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005469/en/

These data were presented as part of a plenary session (Abstract OP37) at the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen, Denmark. At the Congress, Janssen also shared a digital oral presentation with additional data from the UNIFI induction study evaluating the effects of ustekinumab on histo-endoscopic mucosal healing (HEMH), a novel, pre-specified endpoint in this programme.

Results from the maintenance phase of the Phase 3 study demonstrated that 44 percent (90 mg every 8 weeks [q8w]) and 38 percent (90 mg every 12 weeks [q12w]) of patients with moderate to severe UC receiving ustekinumab SC injections achieved clinical remission, as defined by the Mayo score, at week 44 (52 weeks after IV induction) compared to 24 percent of patients who received placebo (p<0.001 and p=0.002, respectively).1 These data were included in submissions to the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) seeking approval of ustekinumab as a treatment for UC.

“Ulcerative colitis is a disruptive, lifelong and potentially debilitating inflammatory bowel disease; however, it is a condition where remission is possible,” said lead study investigator William Sandborn, MD, Chief, Division of Gastroenterology and Professor of Medicine, University of California, San Diego. “The data suggest the potential of ustekinumab as an effective therapy for helping people living with ulcerative colitis achieve remission, as well as providing other meaningful outcomes, including clinical response, histo-endoscopic improvement and corticosteroid-free remission.”

Major secondary endpoints, including maintenance of clinical response, endoscopic improvement, corticosteroid-free remission and maintenance of clinical remission from baseline, were also achieved in greater proportions of patients receiving ustekinumab q8w and q12w injections versus patients receiving placebo. At week 44:

  • 71 percent of patients receiving ustekinumab q8w and 68 percent of patients receiving ustekinumab q12w maintained clinical response, compared with 44 percent of patients receiving placebo (both p<0.001).1 Clinical response was defined as a decrease from baseline in the Mayo score by ≥30 percent and ≥3 points, with a rectal bleeding sub-score of 0 or 1 or a decrease in the rectal bleeding sub-score ≥1
  • 51 percent of patients receiving ustekinumab q8w and 44 percent of patients receiving ustekinumab q12w achieved endoscopic improvement, compared with 29 percent of patients receiving placebo (p<0.001 and p=0.002, respectively).1 Endoscopic improvement was defined as a Mayo endoscopy sub-score of 0 (normal mucosa or inactive disease) or 1 (mild disease activity)
  • 42 percent of patients receiving ustekinumab q8w and 38 percent of patients receiving ustekinumab q12w were in clinical remission and were corticosteroid-free, compared with 23 percent of patients receiving placebo (p<0.001 and p=0.002, respectively).1 The global remission definition was a Mayo score ≤2 points, with no individual sub-score >1

Through to week 44, the proportions of patients with adverse events (AEs), serious AEs, infections and serious infections in the ustekinumab groups were generally comparable to the placebo group. The proportions of patients who discontinued the study agent were lower with ustekinumab q8w and q12w versus placebo. Among the primary population in the maintenance study, no deaths occurred. Two malignancies other than non-melanoma skin cancer (NMSC) (one colon cancer, q8w; one papillary renal cell carcinoma, q12w) were reported. One patient reported NMSC (two squamous cell carcinoma events, q12w).1 Overall, the safety for ustekinumab in UC patients was consistent with the known safety profile of ustekinumab in Crohn’s disease (CD).2

“The UNIFI maintenance data further build the case for ustekinumab as a potential new treatment option for ulcerative colitis and illustrate our ongoing commitment to researching and developing meaningful therapies for people living with inflammatory bowel diseases,” said Scott E. Plevy, M.D., Gastroenterology Disease Area and IL-23 Pathway Leader, Janssen Research & Development, LLC. “Furthermore, we are proud that UNIFI is the first Phase 3 study to report a combined histo-endoscopic endpoint in patients with ulcerative colitis.”

In the abstract (DOP71) presenting the induction study colonic mucosal healing results, patients achieved higher rates of endoscopic improvement, histologic improvement and the combined endpoint of histo-endoscopic mucosal healing (HEMH), versus placebo, 8 weeks after receiving a single IV induction dose of ustekinumab.3 Histo-endoscopic mucosal healing assesses how the colon is responding both histologically and endoscopically to therapy and both have been associated with improved long-term clinical outcomes, such as reduced risk of relapse and need for surgery/hospitalisation, and reduced risk of developing cancer.4

#ENDS#

About the UNIFI trial
UNIFI is a Phase 3 protocol, designed to evaluate the safety and efficacy of ustekinumab induction and maintenance dosing for the treatment of moderate to severe UC in adults who demonstrated an inadequate response to, or were unable to tolerate, conventional (i.e., corticosteroids, immunomodulators) or biologic (i.e., one or more TNF blockers and/or vedolizumab) therapies. Both the induction and maintenance studies are randomised, double-blind, placebo-controlled, parallel group, multicentre studies. The induction study was conducted over a duration of at least 8 weeks for each participant. Participants achieving clinical response in the induction study were eligible for the maintenance study. The maintenance study was 44 weeks in duration. The primary endpoint of the induction study was clinical remission at week 8, and the primary endpoint for the maintenance study was clinical remission at week 44 among responders to a single IV ustekinumab infusion. After completion of the maintenance study, a long-term extension study will follow eligible participants for an additional three years.

About ulcerative colitis
Ulcerative colitis affects up to 2.6 million people in Europe.5 It is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucous. Ulcerative colitis is the result of an abnormal response by the body's immune system. Symptoms vary, but may include loose and more urgent bowel movements, persistent diarrhoea, abdominal pain, bloody stool, loss of appetite, weight loss and fatigue.6

About STELARA ® (ustekinumab) 2
In the European Union, ustekinumab is approved for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or psoralen plus ultraviolet A, and is also indicated for the treatment of moderate to severe plaque psoriasis in adolescent patients aged 12 years and older who are inadequately controlled by or are intolerant to other systemic therapies or phototherapies. In addition, ustekinumab is approved alone or in combination with MTX for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug therapy has been inadequate. In November 2016, the European Commission approved ustekinumab for the treatment of adult patients with moderate to severe CD who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha antagonist or have medical contraindications to such therapies.

The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to ustekinumab. In December 2018, a Group Type II Variation Application to the EMA was submitted, which seeks approval of ustekinumab for the treatment of adults with moderate to severe UC.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/EMEA. Follow us on Twitter: @JanssenEMEA. Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

# # #

References
1. W.J Sandborn, B.E Sands, R. Panaccione, et al. Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 resultus from UNIFI [Abstract OP37]. Presented at European Crohn’s and Colitis Organisation (ECCO 2019) 6-9 March, 2019; Copenhagen, Denmark.
2. European Medicines Agency. (2016) Ustekinumab Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf. Accessed March 2019.
3. K. Li, J.R Friedman, C Marano, et al. Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis [Abstract DOP71]. Presented at European Crohn’s and Colitis Organisation (ECCO 2019) 6-9 March, 2019; Copenhagen, Denmark.
4. GI Health Foundation. What is Mucosal Healing? Available at: http://www.gihealthfoundation.org/GI_news_and_library/library/ppts/IBD/WhatisMucosalHealing.pdf. Accessed March 2019.
5. Ng SC, Shi HY, Underwood FE, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769-78.
6. Crohn’s & Colitis Foundation. What is Ulcerative Colitis? Available at: http://www.crohnscolitisfoundation.org/what-are-crohns-and-colitis/what-is-ulcerative-colitis/. Accessed March 2019.

*Remission was defined as a Mayo score ≤2 points, with no individual sub-score >1. The Mayo score is designed to measure the severity of UC, giving a score from 0–12 points; a higher score indicates more severe disease activity

Limited Liability Company

Contact information

Media Contact:
Emily Bone
Phone: +44 787-639-4360
ebone1@its.jnj.com

Investor Relations:
Christopher DelOrefice
Phone: +1 732-524-2955

Lesley Fishman
Phone: +1 732-524-3922

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

The 26th HKTDC Hong Kong Fashion Week for Spring/Summer Opens in July23.5.2019 04:44:00 EESTTiedote

The 26 th HKTDC Hong Kong Fashion Week for Spring/Summer will curtain up at the Hong Kong Convention and Exhibition Centre from 8-11 July 2019. The four-day fair is expected to welcome some 1,000 exhibitors from across the globe, presenting a wide array of spring/summer clothing, designers’ collections, international brands, garment and fabrics, and fashion accessories. As a premier sourcing platform for global buyers, the Hong Kong Fashion Week is also a gateway to vivacious markets of Mainland China and Asia, making it one of the must-attend global events in the fashion industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005901/en/ (Photo: Business Wire) Click HERE to Register for Your Free e-Badge Themed zones return with splendour The fashion industry has always been fast-paced, and with the adoption of technology, it has the capacity to change even faster and varied in greater extent. The fair has been keepin

CORRECTING AND REPLACING Teleperformance Groups ‘Praxidia Knowledge Services’ partners with CallMiner to launch TP Interact – a Comprehensive Interaction Analytics Solution22.5.2019 21:08:00 EESTTiedote

Please replace the release sent on May 21 2019 03:00 AM ET with the following corrected version due to multiple revisions. The corrected release reads: TELEPERFORMANCE GROUPS ‘PRAXIDIA KNOWLEDGE SERVICES’ PARTNERS WITH CALLMINER TO LAUNCH TP INTERACT – A COMPREHENSIVE INTERACTION ANALYTICS SOLUTION Praxidia Knowledge Services, a specialised subsidiary of the Teleperformance Group, today announced its strategic partnership with CallMiner to launch a customer solution called TP Interact. This speech and customer engagement analytics solution will optimise agent quality and customer satisfaction within contact centres across the globe. TP Interact’s managed analytics and consulting services, powered by the CallMiner Eureka speech analytics platform, is scalable in terms of both capacity and geography. This allows organisations across industry verticals to benefit from the invaluable insights driven by its customer interactions, regardless of call volume or channel. Through this partnershi

Mary Kay Inc.’s David Holl Named Among Top Ten Most Reputable CEOs in the World, According to Reputation Institute22.5.2019 20:00:00 EESTTiedote

Mary Kay Inc., a global beauty brand, today announced that Chairman and CEO David Holl is among the top ten most reputable chief executives in the world according to the Reputation Institute’s CEO RepTrak 2019. The Reputation Institute, the world’s leading provider of reputation measurement, measured the reputation of more than 140 global CEOs and canvassed more than 230,000 individual ratings among the informed public. The study was conducted in January and February of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005604/en/ David Holl, CEO Mary Kay Inc. (Photo: Mary Kay Inc.) “David’s leadership and operational expertise since being named CEO in 2006 has contributed significantly to Mary Kay’s success,” said Richard R. Rogers, son of Mary Kay Ash, co-founder and Executive Chairman of the Board. “Mary Kay is a brand born of purpose, and David’s steadfast commitment to our founding values has made him a tru

Secure-D Exposes Suspicious Android App with 500 Million Downloads22.5.2019 16:49:00 EESTTiedote

Upstream, a leading mobile technology company, has unveiled that the popular Android application VidMate triggers suspicious background activity. Hidden software within the app delivers invisible ads, generates fake clicks and purchases, installs other suspicious apps without consent and collects personal users’ information. Consequently, it depletes users’ data allowance and brings unwanted charges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005501/en/ With over 500 million downloads reported, VidMate is a popular Android application for streaming and downloading videos and songs from services such as Dailymotion, Vimeo, and YouTube. It is not available in the Google Play Store but is distributed through third-party app stores like CNET or Uptodown. According to publicly available information, VidMate was developed by a subsidiary of UC Web, which is owned by Chinese conglomerate Alibaba. Over a recent period Upst

Airship’s Data Study Reveals the State of Global Mobile Permissions One Year into GDPR22.5.2019 16:35:00 EESTTiedote

With GDPR reaching its one year anniversary May 25, customer engagement company Airship today revealed top-level results of its global benchmark study, examining the state of mobile app user permissions across nearly 700 million people worldwide. While marketers trimmed customer lists to meet new regulatory requirements for "traditional" channels (i.e., email), mobile app audiences continue to grow — up globally by +16.6 percent year over year. Businesses are also sending more notifications — averaging 36 per user per month (up 18.4 percent since last year) — while the average notification opt-in rate remains high at over two-thirds (67 percent) of global app users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005486/en/ With mobile app audiences growing around the world, businesses are more heavily leveraging notifications with negligible impact to opt-in rates. (Graphic: Business Wire) These metrics vary at a regio

Diligent Launches Modern Governance to Address Dangerous Governance Deficits and Announces New Modern Governance Summit22.5.2019 16:27:00 EESTTiedote

Today, Diligent Corporation launched a new category, called modern governance, designed to provide leaders with the missing key to bring governance into the digital age, along with new technology and a summit to support this well-designed system. Modern governance is the practice of empowering leaders with technology, insights, and processes to fuel good governance that organizations require to thrive and endure. Modern governance helps organizations address governance deficits. A governance deficit means an organization lacks the security, foresight, and accountability to withstand the onslaught of contemporary challenges – such as activist investors, cyber risk, regulation, diversity and global uncertainty. Feedback from Diligent’s 16,000 clients and the 600,000 leaders who use its technology – including more than 50% of the Fortune 1000, 70% of the FTSE 100, and 65% of the ASX – sparked the need for rethinking how companies and their boards should approach governance to navigate tod

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme